SAGE Open Medical Case ReportsThis case report describes, to our knowledge, the first known successful treatment of airborne allergic contact dermatitis to sesquiterpene lactone with upadacitinib in an adult patient.
Barbara Marzario +2 more
doaj +1 more source
Detection of Exon 12 and 14 Mutations in Janus Kinase 2 Gene Including a Novel Mutant in V617F Negative Polycythemia Vera Patients from Pakistan [PDF]
, 2018 Afia Muhammad Akram +10 more
openalex +1 more source
Journal of Pediatric Gastroenterology and Nutrition, EarlyView.Abstract Objectives Tofacitinib is a selective Janus kinase (JAK‐1) inhibitor approved for the treatment of ulcerative colitis (UC) in adults. Data is limited in the pediatric population. The aim of this study was to evaluate the efficacy of tofacitinib in pediatric inflammatory bowel disease (IBD).
Denise D. Young +10 more
wiley +1 more source
Computational modeling and in vitro evaluation identified natural product—Z218 as a novel Janus kinase 2 (JAK2) inhibitor to combat β‐thalassemia [PDF]
, 2023 Ahmad Shaikh
openalex +1 more source
Gastrointestinal strictures in a pediatric patient with Satoyoshi syndrome
JPGN Reports, EarlyView.Abstract We present a novel case of gastrointestinal strictures in a young girl with Satoyoshi syndrome (SS), highlighting multi‐system features of alopecia universalis, painful muscle cramps with dystonia, aberrant growth velocity, and skeletal abnormalities.
Katherine (Tusia) Pohoreski +5 more
wiley +1 more source
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis [PDF]
, 2020 Pablo A. Olivera +4 more
openalex +1 more source
Efficacy of upadacitinib induction for pediatric inflammatory bowel disease
JPGN Reports, EarlyView.Abstract Objectives Upadacitinib, a second‐generation Janus kinase (JAK) inhibitor, is approved for moderate to severe Crohn's disease (CD) and ulcerative colitis (UC) in adults. Its efficacy in pediatric patients remains unclear, though early reports suggest benefits in refractory inflammatory bowel disease (IBD).
Evan Greenhall +5 more
wiley +1 more source
Turmeric and curcumin: From traditional medicine to modern therapeutic applications
JSFA reports, EarlyView.Abstract Turmeric (Curcuma longa), a medicinal plant, has maintained its cultural and therapeutic significance over centuries in Ayurveda, Unani, and Traditional Chinese Medicine. However, novel formulations and delivery methods are being developed to address these challenges.
Azma Nadeem +7 more
wiley +1 more source
Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review
JEADV Clinical Practice, EarlyView.ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson +4 more
wiley +1 more source
New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa
JEADV Clinical Practice, EarlyView.ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender +2 more
wiley +1 more source